Adicet Bio (LTS:0HX7) Cash And Cash Equivalents : $247.59 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Cash And Cash Equivalents?

Adicet Bio's quarterly cash and cash equivalents declined from Sep. 2023 ($183.26 Mil) to Dec. 2023 ($159.71 Mil) but then increased from Dec. 2023 ($159.71 Mil) to Mar. 2024 ($247.59 Mil).

Adicet Bio's annual cash and cash equivalents declined from Dec. 2021 ($277.54 Mil) to Dec. 2022 ($257.66 Mil) and declined from Dec. 2022 ($257.66 Mil) to Dec. 2023 ($159.71 Mil).

Adicet Bio Cash And Cash Equivalents Historical Data

The historical data trend for Adicet Bio's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Cash And Cash Equivalents Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

10.61

84.33

277.54

257.66

159.71

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															231.64	205.46	183.26	159.71	247.59

Adicet Bio Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Adicet Bio (LTS:0HX7) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Adicet Bio Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (LTS:0HX7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (LTS:0HX7) Headlines

No Headlines